🔗 Share this article

As the United States undertakes unprecedented changes to its immunization schedules, an unexpected name appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has focused upon potential fatalities after COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Program

Public health authorities were set to reveal radical changes to the childhood vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of step with many the global community with no evidence for benefit. The announcement has been delayed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon dismantling previously authorized vaccines at the FDA.

The new acting director has often pushed for ending certain childhood immunization guidelines in the US so as to align more like Denmark, a nation with universal health coverage and a citizenry roughly the population of Wisconsin’s.

So far public appearances, she has continued to focus on vaccines – traditionally the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Questions Over Expertise

The appointee has little discernible background in medication creation, approval processes or leadership, which has been typical for former leaders of the CBER. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous directors of CBER would “grasp legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who headed CBER have had.”

CDER has an enormous range of responsibilities at the FDA, she stated.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office approves a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and more, and each of these have to be supervised,” she said. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial leadership element to the job, which oversees over 5,000 employees. “It’s a enormous administrative position, if you do it right,” Woodcock added.

Agency Reaction and Contentious Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson said that the “inquiries are based on inaccurate premises”.

“Her experience matches the responsibilities of her role,” the official said, pointing to the months Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched expedited review system, a contentious rapid drug-approval program that apparently troubled her preceding directors. “By what process are these therapies being chosen for this fast-track system? Who is making the decisions?” Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent regulations of all drugs, except for shots.”

Documented History on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if concerning, track record, Howard have noted. She released a analysis using unverified volunteer-provided data to assess the frequency of myocarditis after COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the new administration encompassed altering regulations for novel immunizations and ending “optional” vaccines, she stated post-election on a podcast. At the FDA, Høeg has allegedly suggested excluding adolescent males from obtaining COVID-19 vaccinations.

“She is an complete ideologue who commences with her beliefs and reverse-engineers to retrofit the data in a highly misleading, dishonest way,” Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg joined other dissenters, {like|